Astellas Buys 87 Percent Of OSI Of U.S., Extends Time To Buy Rest
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma's acquisition of U.S.-Based OSI Pharmaceuticals has been achieved, the Japanese company said, with purchase of 87 percent of shares